Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ More than 42,000 people took part in the Pfizer COVID-19 vaccine trial

More than 42,000 people took part in the Pfizer COVID-19 vaccine trial



Pfizer will help supply the US government with 100 million doses of coronavirus vaccine under a $ 1.95 billion deal. (Photo: Jeenah Moon / Getty Images)

TO editing
UPDATED 15:49 PT – Monday, October 26, 2020

The US pharmaceutical giant Pfizer has included more than 42,000 people in the second phase 2 trial of its potential COVID-19 vaccine. The company also said more than 35,000 participants received a second dose of vaccination.

The pharmaceutical company is one of the leaders in the coronavirus vaccine race. President Trump also mentioned the company during the last presidential debate.

“Pfizer is doing very well and we have many others,” he said. “And then we have others that we are working on closely with other countries, especially Europe.”

The researchers hope the test results will be available by November, and if so, they will be sent to the FDA for a review process that could take up to four weeks.

MORE NEWS: Officials Arrest 39-Year-Old for Boston, Massachusetts




Source link